Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894928 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05894928 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 21 participants.
The verdict
NCT05894928, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.
Interventions
- DRUG Cholestyramine
- DRUG LOXO-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2023-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05894928
The ClinicalTrials.gov registry entry for NCT05894928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cholestyramine is the first listed.
NCT05894928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05894928 about?
NCT05894928 is a clinical study titled "A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants". The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability...
What is the current status of trial NCT05894928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-06-07. Estimated completion is 2023-07-09.
What interventions are being tested in trial NCT05894928?
The interventions under investigation include: Cholestyramine (DRUG), LOXO-783 (DRUG).
Who is sponsoring clinical trial NCT05894928?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.